A photo-based menstrual blood loss metric

Ended Project Grant Awarded Last action

Award ID
R44HD102235
Recipient
Awarding agency
Obligated
$4,812,712

Award facts

Completion date
Originally
Funding
  • $4,095,458.00 Federal
  • $717,254.00 Non-federal
Place of performance
California, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
In the united states, approximately 30% of reproductive aged women suffer from AUB and the associated symptom of heavy uterine bleeding (MENORRHAGIA), a menstrual disorder that drastically impairs quality of life and has an annual economic burden of $37 billion. Women afflicted by AUB experience limitations in social, physical, and leisure activities, and incur a substantial personal financial burden due to work absence and home management costs (>$2,000 per year). Despite the high prevalence of this medical condition, clinicians rely on women who are distressed by their menses to give a subjective self-assessment of their menstrual blood loss (MBL), which has proven to be unreliable for accurate diagnosis and can lead to unnecessary surgery. Given that these symptoms account for one-third of all office visits to the gynecologist, choosing an appropriate treatment course is critical for providing high-quality care to americans. Current methods for quantifying MBL have key drawbacks that limit their use. Alkaline hematin (AH) testing is the standard required by regulatory bodies for objective quantification of MBL. Unfortunately, AH testing is impractical for routine clinical practice as IT is expensive (~$1000 per cycle) and has poor acceptability, requiring patients to collect all used sanitary products and mail them to a lab facility for analysis. While pictorial blood loss assessment charts (PBLACS) offer a less costly, semi-quantitative method for MBL quantification, they demonstrate a high rate of false positive results (~59%), which leads to the over-diagnosis of MENORRHAGIA. To address the need for a cost-effective, easy- to-use, and objective method to quantify MBL in premenopausal women, theranova has developed a cell phone- based diagnostic tool, the electronic MBL diary (EMBLD). Previously, in a proof of concept clinical study, we demonstrated a strong correlation between EMBLD and AH testing, the gold-standard method for objective quantification of MBL. The goals of this phase II proposal are to determine the effectiveness of our device for accurately diagnosing MENORRHAGIA. First, we will verify the sensitivity of the image processing algorithm to accurately quantify MBL in women with both normal and heavy menses (specific aim 1). Second, we will conduct a pivotal clinical study to validate the effectiveness of EMBLD for diagnosing MENORRHAGIA (specific aim 2). The data obtained will support FDA 510(K) clearance and will allow US to commercialize the system within four years of the funding of this proposal.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $608,576 $0
Amendment $608,576 $0
Amendment $721,899 $0
Amendment $721,899 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $717,254 $0
Original award $717,254 $717,254
Show all 12

Quick answers

Who received award R44HD102235?

R44HD102235 was awarded to Theranova LLC by National Institute of Child Health and Human Development (National Institutes of Health) on September 23, 2021.

How much is award R44HD102235 worth?

$4,812,712 has been obligated on R44HD102235: $4,095,458 in federal funding and $717,254 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login